Clinical Trials Browser

Phase 2/3 × Camurati-Engelmann Syndrome × pembrolizumab × Clear all

NCT06788990 2026-03-05

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome